| Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults (NCT02741128) | Sanofi Pasteur, a Sanofi Company | 2019-11-06 |
| Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients (NCT03432442) | Mahidol University | 2018-09-04 |
| Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects (NCT02992418) | Sanofi Pasteur, a Sanofi Company | 2016-12-19 |
| Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine (NCT02948933) | Sanofi Pasteur, a Sanofi Company | 2016-12-14 |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® (NCT02993757) | Sanofi Pasteur, a Sanofi Company | 2016-12-01 |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® (NCT02979535) | Sanofi Pasteur, a Sanofi Company | 2016-11-16 |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule (NCT02824198) | Sanofi Pasteur, a Sanofi Company | 2016-07-01 |
| Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age (NCT02628444) | Sanofi Pasteur, a Sanofi Company | 2016-05-02 |
| Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule (NCT02623725) | Sanofi Pasteur, a Sanofi Company | 2016-04-14 |
| Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine (NCT01943825) | Sanofi Pasteur, a Sanofi Company | 2013-11-05 |
| Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study (NCT01983553) | Sanofi Pasteur, a Sanofi Company | 2013-09-10 |
| Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India (NCT01550289) | Sanofi Pasteur, a Sanofi Company | 2012-03-01 |
| Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine (NCT01488890) | Sanofi Pasteur, a Sanofi Company | 2011-12-06 |
| Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers (NCT01436396) | Sanofi Pasteur, a Sanofi Company | 2011-09-07 |
| Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children (NCT01477671) | Sanofi Pasteur, a Sanofi Company | 2011-09-01 |
| Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers (NCT01411241) | Sanofi Pasteur, a Sanofi Company | 2011-07-18 |
| Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America (NCT01374516) | Sanofi Pasteur, a Sanofi Company | 2011-06-08 |
| Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia (NCT01373281) | Sanofi Pasteur, a Sanofi Company | 2011-06-03 |
| Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia (NCT01134263) | Sanofi Pasteur, a Sanofi Company | 2010-10-05 |
| Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America (NCT01187433) | Sanofi Pasteur, a Sanofi Company | 2010-08-01 |
| A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines (NCT01064141) | Sanofi | 2010-01-01 |
| Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America (NCT00993447) | Sanofi Pasteur, a Sanofi Company | 2009-10-01 |
| Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus (NCT00919178) | National Institute of Allergy and Infectious Diseases (NIAID) | 2009-07-01 |
| Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore (NCT00880893) | Sanofi Pasteur, a Sanofi Company | 2009-04-07 |
| Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects (NCT00875524) | Sanofi Pasteur, a Sanofi Company | 2009-03-01 |
| Efficacy and Safety of Dengue Vaccine in Healthy Children (NCT00842530) | Sanofi Pasteur, a Sanofi Company | 2009-02-01 |
| Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years (NCT00788151) | Sanofi Pasteur, a Sanofi Company | 2008-09-26 |
| Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults (NCT00740155) | Sanofi Pasteur, a Sanofi Company | 2008-08-01 |
| Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US (NCT00617344) | Sanofi | 2008-04-17 |
| A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children (NCT00468858) | U.S. Army Medical Research and Development Command | 2007-07-01 |
| Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus (NCT00458120) | National Institute of Allergy and Infectious Diseases (NIAID) | 2007-03-01 |
| Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects (NCT00730288) | Sanofi | 2006-08-01 |